The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

Moreover, 15% of them were taking LAMA or LABA therapies in combination ... approval and launch of the company's lead drug candidate into the large COPD market in late 2023 or 2024.

The CRYSTAL study is the first LABA/LAMA pragmatic ... from other COPD treatments, such as inhaled steroid-containing combination therapies," said Vasant Narasimhan, Global Head Drug Development ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

Also in November 2024, the Company completed enrollment in a Phase 2 dose-ranging trial with glycopyrrolate, a LAMA ... of our drug Ohtuvayre to treat adult patients in the US with COPD ...

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

Ligand's Q4 2024 revenue increased by 52% year-over-year. The company reported a 40% increase in core adjusted EPS for the full year. Ligand ended 2024 with $256 million in cash and investments ...